Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2009 4
2011 1
2012 1
2013 2
2014 3
2015 2
2016 1
2017 4
2018 3
2019 4
2020 3
2021 4
2022 4
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers.
Fischer-Riepe L, Kailayangiri S, Zimmermann K, Pfeifer R, Aigner M, Altvater B, Kretschmann S, Völkl S, Hartley J, Dreger C, Petry K, Bosio A, von Döllen A, Hartmann W, Lode H, Görlich D, Mackensen A, Jungblut M, Schambach A, Abken H, Rossig C. Fischer-Riepe L, et al. Among authors: altvater b. Clin Cancer Res. 2024 Apr 9:OF1-OF14. doi: 10.1158/1078-0432.CCR-23-3157. Online ahead of print. Clin Cancer Res. 2024. PMID: 38593230
CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process.
Altvater B, Kailayangiri S, Spurny C, Flügge M, Meltzer J, Greune L, Urban K, Schwöppe C, Brand C, Schliemann C, Hintelmann H, Harrach S, Hartmann W, Abken H, Kuehle J, Schambach A, Görlich D, Berdel WE, Rossig C. Altvater B, et al. Cancer Gene Ther. 2023 Oct;30(10):1355-1368. doi: 10.1038/s41417-023-00642-x. Epub 2023 Jun 30. Cancer Gene Ther. 2023. PMID: 37391502 Free PMC article.
Relevance of Abnormal KCNN1 Expression and Osmotic Hypersensitivity in Ewing Sarcoma.
Fuest S, Post C, Balbach ST, Jabar S, Neumann I, Schimmelpfennig S, Sargin S, Nass E, Budde T, Kailayangiri S, Altvater B, Ranft A, Hartmann W, Dirksen U, Rössig C, Schwab A, Pethő Z. Fuest S, et al. Among authors: altvater b. Cancers (Basel). 2022 Oct 1;14(19):4819. doi: 10.3390/cancers14194819. Cancers (Basel). 2022. PMID: 36230742 Free PMC article.
Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse.
Berdel AF, Ruhnke L, Angenendt L, Wermke M, Röllig C, Mikesch JH, Scheller A, Hemmerle T, Matasci M, Wethmar K, Kessler T, Gerwing M, Hescheler D, Schäfers M, Hartmann W, Altvater B, Rossig C, Bornhäuser M, Lenz G, Stelljes M, Rueter B, Neri D, Berdel WE, Schliemann C. Berdel AF, et al. Among authors: altvater b. Blood Adv. 2022 Jun 28;6(12):3684-3696. doi: 10.1182/bloodadvances.2021006909. Blood Adv. 2022. PMID: 35468621 Free PMC article. Clinical Trial.
GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18.
Glienke W, Dragon AC, Zimmermann K, Martyniszyn-Eiben A, Mertens M, Abken H, Rossig C, Altvater B, Aleksandrova K, Arseniev L, Kloth C, Stamopoulou A, Moritz T, Lode HN, Siebert N, Blasczyk R, Goudeva L, Schambach A, Köhl U, Eiz-Vesper B, Esser R. Glienke W, et al. Among authors: altvater b. Front Immunol. 2022 Mar 24;13:839783. doi: 10.3389/fimmu.2022.839783. eCollection 2022. Front Immunol. 2022. PMID: 35401506 Free PMC article.
Generation of an NFκB-Driven Alpharetroviral "All-in-One" Vector Construct as a Potent Tool for CAR NK Cell Therapy.
Rudek LS, Zimmermann K, Galla M, Meyer J, Kuehle J, Stamopoulou A, Brand D, Sandalcioglu IE, Neyazi B, Moritz T, Rossig C, Altvater B, Falk CS, Abken H, Morgan MA, Schambach A. Rudek LS, et al. Among authors: altvater b. Front Immunol. 2021 Nov 3;12:751138. doi: 10.3389/fimmu.2021.751138. eCollection 2021. Front Immunol. 2021. PMID: 34804035 Free PMC article.
Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation.
Schliemann C, Kessler T, Berdel AF, Hemmerle T, Angenendt L, Altvater B, Rossig C, Mikesch JH, Lenz G, Schäfers M, Neri D, Stelljes M, Berdel WE. Schliemann C, et al. Among authors: altvater b. Br J Haematol. 2021 Mar;192(6):e148-e151. doi: 10.1111/bjh.17365. Epub 2021 Feb 22. Br J Haematol. 2021. PMID: 33618424 Clinical Trial. No abstract available.
35 results